According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.41. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter valued at $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the first quarter valued at $28,000. Finally, Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter valued at $29,000.